X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7954) 7954
Newsletter (49) 49
Magazine Article (11) 11
Book Chapter (4) 4
Book / eBook (3) 3
Conference Proceeding (3) 3
Book Review (1) 1
Newspaper Article (1) 1
Publication (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5190) 5190
animals (4027) 4027
oligopeptides - therapeutic use (3213) 3213
male (2988) 2988
oligopeptides - pharmacology (2630) 2630
female (2183) 2183
mice (2011) 2011
oligopeptides - chemistry (1656) 1656
pharmacology & pharmacy (1497) 1497
rats (1285) 1285
peptides (1240) 1240
oligopeptides - administration & dosage (1154) 1154
middle aged (1127) 1127
adult (976) 976
cell line, tumor (871) 871
oligopeptides - metabolism (846) 846
biochemistry & molecular biology (824) 824
cancer (730) 730
oligopeptides - adverse effects (728) 728
oncology (724) 724
treatment outcome (708) 708
aged (671) 671
analysis (655) 655
expression (655) 655
drug therapy, combination (650) 650
proteins (643) 643
antiviral agents - therapeutic use (639) 639
disease models, animal (629) 629
amino acid sequence (624) 624
research (607) 607
dose-response relationship, drug (589) 589
oligopeptides (572) 572
therapy (536) 536
atazanavir sulfate (529) 529
hepatitis c, chronic - drug therapy (526) 526
apoptosis (514) 514
health aspects (505) 505
oligopeptides - pharmacokinetics (504) 504
cell biology (489) 489
rats, sprague-dawley (482) 482
hiv infections - drug therapy (479) 479
immunology (458) 458
in-vitro (450) 450
cells, cultured (438) 438
time factors (435) 435
care and treatment (425) 425
antineoplastic agents - therapeutic use (418) 418
mice, inbred c57bl (415) 415
pyridines - therapeutic use (409) 409
proline - analogs & derivatives (405) 405
mice, inbred balb c (401) 401
infectious diseases (394) 394
cells (387) 387
apoptosis - drug effects (381) 381
medicine, research & experimental (381) 381
neurosciences (380) 380
ribavirin - therapeutic use (380) 380
research article (378) 378
medicine (375) 375
multidisciplinary sciences (375) 375
oligopeptides - chemical synthesis (375) 375
mice, nude (368) 368
chemistry, multidisciplinary (359) 359
in-vivo (358) 358
molecular sequence data (356) 356
drug therapy (355) 355
drug delivery systems (353) 353
tumors (353) 353
inflammation (352) 352
peptide (345) 345
cell line (341) 341
gastroenterology & hepatology (340) 340
activation (331) 331
nanoparticles (331) 331
ligands (330) 330
interferon-alpha - therapeutic use (326) 326
protease inhibitors (324) 324
physiological aspects (321) 321
antineoplastic agents - pharmacology (317) 317
hepacivirus - genetics (317) 317
hepatitis c (316) 316
proline - therapeutic use (313) 313
chemistry, medicinal (308) 308
hematology (308) 308
telaprevir (306) 306
drugs (295) 295
rats, wistar (294) 294
gene expression (292) 292
cell survival - drug effects (291) 291
polyethylene glycols - therapeutic use (287) 287
angiogenesis (286) 286
microbiology (286) 286
binding (283) 283
genotype (283) 283
protein binding (282) 282
inhibition (279) 279
cell proliferation - drug effects (272) 272
hepatitis c virus (271) 271
medicine & public health (267) 267
ribavirin (259) 259
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7697) 7697
Russian (139) 139
Japanese (84) 84
German (55) 55
Spanish (52) 52
French (32) 32
Chinese (22) 22
Hungarian (6) 6
Italian (6) 6
Danish (5) 5
Polish (5) 5
Ukrainian (4) 4
Czech (3) 3
Finnish (3) 3
Dutch (2) 2
Swedish (2) 2
Croatian (1) 1
Hebrew (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
.... This review article is structured to discuss antiviral therapeutics on the basis of these 3 major antiviral categories, with the caveat that some drugs discussed... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
European heart journal, ISSN 1522-9645, 2016, Volume 38, Issue 13, pp. ehw145 - 941d
Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations 
PERMEABILITY TRANSITION PORE | PROTEIN KINASE-C | MICROVASCULAR OBSTRUCTION | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLOSPORINE-A | CELLULAR BIOLOGY | BYPASS GRAFT-SURGERY | ISCHEMIA-REPERFUSION | LEFT-VENTRICULAR FUNCTION | LONG-TERM BENEFIT | Myocardial Reperfusion Injury - etiology | Nucleotides, Cyclic - metabolism | Ischemic Postconditioning - methods | Vasodilator Agents - therapeutic use | Humans | Oximes - therapeutic use | Nitric Oxide - therapeutic use | Oligopeptides - therapeutic use | Patient Selection | ST Elevation Myocardial Infarction - therapy | Cardiotonic Agents - therapeutic use | Mitochondrial Membrane Transport Proteins - physiology | Adenosine - therapeutic use | Hypothermia, Induced - methods | ST Elevation Myocardial Infarction - complications | ST Elevation Myocardial Infarction - etiology | Coronary Vessels - physiology | Metoprolol - therapeutic use | Combined Modality Therapy | Protein Kinase C - antagonists & inhibitors | Enzyme Inhibitors - therapeutic use | Nitrites - therapeutic use | Cyclosporine - therapeutic use | Myocardial Reperfusion - adverse effects | Signal Transduction - physiology | Clinical Trials as Topic - methods | Nitric Oxide - metabolism | Secosteroids - therapeutic use | Myocardial Reperfusion Injury - prevention & control | Life Sciences | Current Opinion | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133028
Background The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C virus (HCV) infection is limited in HIV/HCV-coinfected... 
TELAPREVIR | PHARMACOKINETICS | SOFOSBUVIR | MULTIDISCIPLINARY SCIENCES | RESISTANCE | GENOTYPE 1 INFECTION | OPEN-LABEL | RETREATMENT | HEPATITIS-C | LEDIPASVIR | TREATMENT FAILURE | Recombinant Proteins - therapeutic use | Hepatitis C, Chronic - pathology | Coinfection | Injections, Intravenous | Prospective Studies | Humans | Middle Aged | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | HIV - drug effects | Oligopeptides - therapeutic use | RNA, Viral - antagonists & inhibitors | HIV Infections - pathology | Patient Safety | Adult | Female | Protease Inhibitors - therapeutic use | HIV Infections - blood | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Silymarin - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | HIV - growth & development | Antiretroviral Therapy, Highly Active | Liver Cirrhosis - virology | Liver Cirrhosis - pathology | HIV Infections - drug therapy | Hepacivirus - growth & development | Viral Load - drug effects | Infection | Highly active antiretroviral therapy | Liver diseases | RNA | Protease inhibitors | Comorbidity | Proteases | Patient outcomes | Liver | Biological products industry | Interferon | Hepatitis C virus | Therapy | Intravenous administration | Viruses | Infections | Mental depression | Epidemiology | Ribavirin | Clinical outcomes | Hepatitis | Genotype & phenotype | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Quality | Hepatology | Human immunodeficiency virus--HIV | Gastroenterology | Safety | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | Virology | Infectious diseases | Hospitals | Silibinin | Fibrosis | Hepatitis C | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 6, p. CD004452
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 12, p. CD008394
Background The frequency of skin ulceration makes it an important contributor to the morbidity burden in people with sickle cell disease. Many treatment... 
Anemia, Sickle Cell | SICKLE CELL DISEASE | HAEMOGLOBINOPATHIES | Leg Ulcer | Bandages | Oligopeptides | Isoxsuprine | TREATMENT | Other treatments | Sickle cell ulcers | Arginine | Butyrates | Complementary & alternative medicine | SKIN | Ulcers (other) | Skin & wounds | Genetic disorders | Wounds | CHRONIC WOUNDS | Skin disorders | Carnitine | Randomized Controlled Trials as Topic | Blood disorders | Ulcers | Anti‐Bacterial Agents | Actihaemyl | Medicine General & Introductory Medical Sciences | Butyrates [therapeutic use] | Carnitine [therapeutic use] | Isoxsuprine [therapeutic use] | ARGININE BUTYRATE | Leg Ulcer [drug therapy; etiology] | QUALITY | ULCERATION | Humans | HEMOLYSIS | Anti-Bacterial Agents [therapeutic use] | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | L-CARNITINE | Anemia, Sickle Cell [complications] | THERAPY | Oligopeptides [therapeutic use] | GM-CSF | MOLGRAMOSTIM | NITRIC-OXIDE | Actihaemyl [therapeutic use] | Arginine [analogs & derivatives; therapeutic use] | Leg Ulcer - etiology | Anemia, Sickle Cell - complications | Arginine - analogs & derivatives | Actihaemyl - therapeutic use | Oligopeptides - therapeutic use | Anti-Bacterial Agents - therapeutic use | Isoxsuprine - therapeutic use | Butyrates - therapeutic use | Carnitine - therapeutic use | Arginine - therapeutic use | Leg Ulcer - drug therapy
Journal Article
Journal Article